Hematopoietic cell transplantation does not prevent myelopathy in X-linked adrenoleukodystrophy: a retrospective study

Journal of Inherited Metabolic Disease

Volumn 38, Issue 2, 2015, Pages 359-361

  van Geel, Björn M ^a,e   Poll The, Bwee Tien ^b   Verrips, Aad ^c   Boelens, Jaap Jan ^d   Kemp, Stephan ^b   Engelen, Marc ^b,e  

^a Northwest Clinics   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENOLEUKODYSTROPHY; ARTICLE; CELL TRANSPLANTATION; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; FOLLOW UP; HEMATOPOIETIC CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MALE; NEUROLOGIC EXAMINATION; OBSERVATIONAL STUDY; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SCHOOL CHILD; SPINAL CORD DISEASE; X LINKED ADRENOLEUKODYSTROPHY; ADOLESCENT; ADULT; AGE; COMPLICATION; DISEASE COURSE; SPINAL CORD DISEASES; TIME; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADRENOLEUKODYSTROPHY; ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; RETROSPECTIVE STUDIES; SPINAL CORD DISEASES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84925482951     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-014-9797-1     Document Type: Article

References (12)

1. Dubey P, Raymond GV, Moser AB, Kharkar S, Bezman L, Moser HW (2005) Adrenal insufficiency in asymptomatic adrenoleukodystrophy patients identified by very long-chain fatty acid screening. J Pediatr 146:528–532
2. Engelen M, Kemp S, de Visser M et al (2012) X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet J Rare Dis 7:51
3. Engelen M, Barbier M, Dijkstra IM et al (2014) X-linked adrenoleukodystrophy in women: a cross-sectional cohort study. Brain 137:693–706
4. Kemp S, Berger J, Aubourg P (2012) X-linked adrenoleukodystrophy: clinical, metabolic, genetic and pathophysiological aspects. Biochim Biophys Acta 1822:1465–1474
5. Miller WP, Rothman SM, Nascene D et al (2011) Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report. Blood 118:1971–1978
6. Moser HW, Moser AB, Frayer KK et al (1981) Adrenoleukodystrophy: increased plasma content of saturated very long chain fatty acids. Neurology 31:1241–1249
7. Moser HW, Smith KD, Watkins PA, Powers J, Moser AB (2001) X-linked adrenoleukodystrophy. In The metabolic and molecular bases of inherited disease. McGraw Hill, New York 3257–3301.
8. Powers JM, Schaumburg HH, Johnson AB, Raine CS (1980) A correlative study of the adrenal cortex in adreno-leukodystrophy–evidence for a fatal intoxication with very long chain saturated fatty acids. Invest Cell Pathol 3:353–376
9. Powers JM, DeCiero DP, Ito M, Moser AB, Moser HW (2000) Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy. J Neuropathol Exp Neurol 59:89–102
10. Schaumburg HH, Powers JM, Raine CS, Suzuki K, Richardson EP Jr (1975) Adrenoleukodystrophy. A clinical and pathological study of 17 cases. Arch Neurol 32:577–591
11. Singh I, Moser AE, Moser HW, Kishimoto Y (1984) Adrenoleukodystrophy: impaired oxidation of very long chain fatty acids in white blood cells, cultured skin fibroblasts, and amniocytes. Pediatr Res 18:286–290
12. van Geel BM, Assies J, Haverkort EB et al (1999) Progression of abnormalities in adrenomyeloneuropathy and neurologically asymptomatic X-linked adrenoleukodystrophy despite treatment with "Lorenzo's oil". J Neurol Neurosurg Psychiatry 67:290–299